Lv3
380 积分 2021-07-12 加入
Small cell lung cancer
17天前
已完结
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
21天前
已完结
Medical treatment for active breast cancer brain metastases
3个月前
已完结
3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)
4个月前
已关闭
The incredible journey: From megakaryocyte development to platelet formation
5个月前
已完结
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
5个月前
已完结
ALK in cancer: from function to therapeutic targeting
6个月前
已完结
Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
6个月前
已完结
皖公网安备34019202002308
